Scleroderma Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
(Albany, US) DelveInsight has launched a new report on Scleroderma Market Insights, Epidemiology, and Market Forecast-2030.
DelveInsight’s ” Scleroderma Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Scleroderma, historical and forecasted epidemiology as well as the Scleroderma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of Scleroderma facts:
- In the United States, the prevalence of scleroderma is 240 per million and an annual incidence of 19 per million.
- In Europe, the prevalence of scleroderma is estimated to be between 10 and 150 per million people, while the annual incidence has been reported to be between 3 and 28 per million people.
- Women are four times more prone to develop systemic scleroderma than men.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/scleroderma-market
Scope of Scleroderma Reports:
- The report covers the descriptive overview of Scleroderma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Scleroderma epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Scleroderma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Scleroderma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Scleroderma market
Request for Free Sample Report: https://www.delveinsight.com/sample-request/scleroderma-market
Scleroderma, or systemic sclerosis, is a chronic connective tissue disease generally classified as one of the autoimmune rheumatic diseases. It causes tissue throughout the body, including the lungs and other organs, to thicken and scar. SSc-ILD is a progressive lung disease in which lung function declines over time, and it can be debilitating and life-threatening. ILD is the leading cause of death among people with scleroderma, typically resulting from a loss of pulmonary function that occurs when the lungs cannot supply enough oxygen to the heart. Scleroderma is majorly of two types: localized scleroderma and systemic sclerosis (SSc).
Scleroderma Companies:
- Boehringer Ingelheim International GmbH
- Corbus Pharmaceuticals Holdings, Inc.
- Bayer AG
- Gilead Sciences, Inc.
- Allergan, Inc.
- Pfizer, Inc.
- Sanofi
- GlaxoSmithKline plc
- Cumberland Pharmaceuticals, Inc.
- Actelion Pharmaceuticals, Inc.
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/scleroderma-market
Table of Contents:
1. Key Insights
2. Executive Summary of Scleroderma
3. Competitive Intelligence Analysis for Scleroderma
4. Scleroderma: Market Overview at a Glance
5. Scleroderma: Disease Background and Overview
6. Patient Journey
7. Scleroderma Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Scleroderma Treatment
11. Marketed Products
12. Emerging Therapies
13. Scleroderma: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Scleroderma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/scleroderma-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/scleroderma-market